February 20, 2025
Antibody-mediated rejection is an important determinant of allograft survival. Our understanding of antibody-mediated rejection has increased dramatically since the era when only hyperacute antibod...
Parmjeet Randhawa
February 20, 2025
Chronic kidney disease affects 14% of the U.S. population1 and is associated with an extraordinarily high risk of poor outcomes, including progression to end-stage kidney disease, cardiovascular ev...
David E. Leaf, Nisha Bansal
February 20, 2025
To the Editor: Ridker et al. (Dec. 5 issue)1 conducted an important analysis of inflammation, cholesterol, and lipoprotein(a) as predictors of long-term cardiovascular outcomes in women. Of concern...
February 20, 2025
A 62-year-old man was admitted because of postprandial abdominal pain and weight loss. Cirrhosis had reportedly been diagnosed 1 year earlier; imaging showed portal vein thrombosis. A diagnosis was...
Gabrielle K. Bromberg, Jonathan N. Glickman
February 20, 2025
Catheter ablation as a treatment for ventricular tachycardia has lagged behind ablation procedures for atrial arrhythmias in becoming an established first-line therapy. Barriers to the study of cat...
Timothy M. Markman
February 20, 2025
Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tac...
John L. Sapp, George A. Wells
February 20, 2025
A 19-year-old beach lifeguard from southern California presented with two asymptomatic, erythematous, raised, serpiginous eruptions on the posterior and right lateral surfaces of the neck.
Amanda Truong, Stephanie Martin
February 20, 2025
To the Editor: In the EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial, Cho et al. (Dec. 5 issue)1 f...
February 20, 2025
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti...
Jennifer R. Brown, Paolo Ghia
February 20, 2025
In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease pr...
The EMPA-KIDNEY Collaborative Group
February 20, 2025
Yellow fever vaccine is highly effective with a single dose, but vaccine supply is limited. The minimum dose requirements for seroconversion remain unknown.In this double-blind, randomized, noninfe...
Derick Kimathi, George M. Warimwe
February 20, 2025
A 37-year-old man presented with a 10-month history of dry cough, fatigue, and dry mouth. Chest radiography showed reticular opacities at the lung bases and cystic lucencies in both lungs.
